Cargando…
Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen
Preclinical models and clinical studies have shown that anti-CD20-based treatment has multifaceted consequences on T-cell immunity. We have performed a prospective study of peripheral T-cell compartment in FL patients, all exhibiting high tumor burden and receiving rituximab-chemotherapy-based regim...
Autores principales: | Milcent, B., Josseaume, N., Petitprez, F., Riller, Q., Amorim, S., Loiseau, P., Toubert, A., Brice, P., Thieblemont, C., Teillaud, J.-L., Sibéril, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748924/ https://www.ncbi.nlm.nih.gov/pubmed/31530876 http://dx.doi.org/10.1038/s41598-019-50029-y |
Ejemplares similares
-
Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients
por: Milcent, Benoit, et al.
Publicado: (2019) -
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?
por: Deligne, Claire, et al.
Publicado: (2017) -
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012) -
Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020) -
Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated”
por: Pahalyants, Vartan, et al.
Publicado: (2022)